Enoxaparin as Treatment for Vulvodynia

Western Galilee Hospital-Nahariya

Status and phase: Completed; Phase 2

Conditions: Vulvodynia

Treatments: Drug: Clexane (enoxaparin)

Study type: Interventional

Funder types: Other

Identifiers

NCT00874484

JB 2409

Details and patient eligibility

About

The investigators hypothesize that injections of Low molecular weight heparin (LMWH) [enoxaparin] will reduce pain in women with vulvodynia.

Enrollment: 40 estimated patients

Sex: Female

Ages: 19 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• women with vulvodynia

Exclusion criteria

• women without vulvodynia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

40 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: Clexane (enoxaparin)

2

Placebo Comparator group

Treatment:

Drug: Clexane (enoxaparin)